<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892502</url>
  </required_header>
  <id_info>
    <org_study_id>2007-007652-34</org_study_id>
    <nct_id>NCT00892502</nct_id>
  </id_info>
  <brief_title>Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?</brief_title>
  <acronym>Bismuth-PBH</acronym>
  <official_title>Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with Bismuth can reduce the
      toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate a possible protective effect of bismuth on the mucous membranes during chemotherapy and radiotherapy</measure>
    <time_frame>daily during treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify the effect of bismuth on the regulation of metallothionein in tumour tissue and healthy tissue, respectively</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hematological Diseases</condition>
  <condition>Hematological Malignancies</condition>
  <condition>Blood Diseases</condition>
  <condition>Malignant Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, containing no active substance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth tablets</intervention_name>
    <description>1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of 18 years or over referred to the Department of Haematology L, Herlev
             Hospital, with a view to 'cytostatic'? treatment of or radiotherapy for haematological
             malignancy

        Exclusion Criteria:

          -  Pregnant women and nursing mothers

          -  No informed consent from patient

          -  Known hyper sensitivity to bismuth or other tablet content

          -  Severe renal insufficiency with creatinin clearance below 25 ml/min.

          -  Patients receiving other treatment for protection of the mucous membrane except cryo
             treatment of the oral cavity (lumps of ice in the mouth)

          -  Other experimental treatment within past four weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per B Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haematology, Copenhagen University Hospital at Herlev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Haematology L, Herlev Hospital, Herlev Ringvej 75</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>haematology</keyword>
  <keyword>haematological</keyword>
  <keyword>hematology</keyword>
  <keyword>hematological</keyword>
  <keyword>malignancy</keyword>
  <keyword>lymphoma</keyword>
  <keyword>myeloma</keyword>
  <keyword>leukemia</keyword>
  <keyword>blood diseases</keyword>
  <keyword>malignant</keyword>
  <keyword>bismuth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

